Development of a Biorelevant Dissolution Test Using Bicarbonate Buffer and Apex Vessel to Predict Clinical...

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery
• Analytical Chemistry

Background:

• Current dissolution tests often fail to predict clinical bioequivalence (BE).
• Enteric-coated drug formulations require specialized dissolution testing.
• Reliable prediction of therapeutic equivalence is crucial for drug development.

Purpose of the Study:

• To develop a biorelevant dissolution test capable of predicting clinical bioequivalence (BE).
• To evaluate enteric-coated pellets of esomeprazole magnesium trihydrate (ECP-ESO) for BE and non-BE (NBE) status.
• To compare biorelevant conditions with compendial dissolution methods.

Main Methods:

• Dissolution testing of ECP-ESOs using paddle method under various conditions.
• Utilized biorelevant bicarbonate buffer (BCB) with a floating lid to simulate intestinal fluid.
• Employed an apex vessel (Apex-V) to suppress artifact cone formation (coning).
• Compared BCB/Apex-V with compendial phosphate buffer (PPB) and round-bottom vessel (RB-V).

Main Results:

• Compendial conditions (PPB/RB-V) failed to distinguish between BE and NBE formulations.
• Apex-V eliminated coning but lacked discriminative power with PPB or BCB alone.
• The combination of biorelevant BCB and Apex-V successfully differentiated BE from NBE ECP-ESOs.
• Results correlated with clinical bioequivalence data.

Conclusions:

• Biorelevant dissolution testing using BCB and Apex-V accurately predicts clinical BE/NBE.
• This simple, biorelevant method enhances prediction capabilities in formulation development.
• The developed test offers a practical approach to assess therapeutic equivalence.